Table 3 Preclinical studies using passive immunotherapy in vivo

Chai (2011) [54]

PHF1 (p396/p404) & MC1 (conformational)

JPNL3 (4R0N/P301L) 2M & PS19 (4R1N/P301S) 2M

JPNL3 2M, 3x/week (15mg/kg i.p.) then 2M, 2x/week (10mg/kg i.p.) & PS19 2M, 2x/week (15mg/kg i.p.)

↓ P-tau, NC micro- and astrogliosis, ↓ weight loss & motor impairment

Boutajangout (2011) [41]

PHF1

JPNL3 2-3M

3M, 1x/week (250ug/mouse i.p.)

↓ P-tau, ↓insoluble tau, NC astro- and microgliosis, improvement traverse beam task, NC rotarod

D'Abramo (2013) [66]

PHF1, MC1 & DA31 (aa150-190)

JPNL3 3M, 6M & 7M

4M, 1x/week (250ug/mouse/i.p.) & survival analysis, 1x/week (250ug/mouse i.p.)

Only MC1 effective. ↓ P-tau, ↓insoluble tau, NC survival, NC micro- and astrogliosis

Castillo-Carranza (2014) [53]

TOMA (conformational)

JPNL3 8M

Single injection (30ug/mouse i.v. & 1ug/mouse i.c.v)

↓Tau oligomers, NC microgliosis and cytokines, improved cognition & motor deficits

Castillo-Carranza (2014) [50]

TOMA

hTau (6 isoforms) 3M (injected with tau oligomers)

Single injection & 6M complex schedule (60ug/mouse i.v. )

↓tau oligomers, NC inflammation, improved cognition

Castillo-Carranza (2015) [51]

TOMA

Tg2576 (APPSWE) 14M

Single injection (30ug/mouse i.v.)

↓tau oligomers, ↓Aβ oligomers, ↑ plaques, NC microgliosis and cytokines, NC synapse loss, improved cognition

Sankaranarayanan (2015) [258]

PHF6 (p231) & PHF13 (p396)

rTg4510 (4R0N/P301L) 3M & PS19 (injected with PFF)

rTg4510 3M, 1x/week (25mg/kg i.p.) & PS19 4W, 1x/week (30mg/kg i.p.)

rTg4510: ↓Soluble P-tau, NC insoluble tau, NC inflammation, NC or improved cognition. PS19-PFF: ↓Tau spreading, improved cognition

Dai (2017) [69]

43D (aa6-18) & 77E9 (aa184-195)

3xTg (4R02/P301L) 12M

2W & 6W, 1x/week (15ug/mouse i.v.)

↓P-tau, improved cognition, ↑activated microglia morphology, ↑complement (C1q & C9), ↓plaques